{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T04:10:16Z","timestamp":1791432616936,"version":"4.3.3"},"reference-count":34,"publisher":"American Society for Microbiology","issue":"11","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2011,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>In clinical practice, antifungal therapy may be switched from fluconazole to voriconazole; such sequential use poses the potential for drug interaction due to cytochrome P450 2C19 (CYP2C19)-mediated inhibition of voriconazole metabolism. This open-label, randomized, two-way crossover study investigated the effect of concomitant fluconazole on voriconazole pharmacokinetics in 10 subjects: 8 extensive metabolizers and 2 poor metabolizers of CYP2C19. The study consisted of 4-day voriconazole-only and 5-day voriconazole-plus-fluconazole treatments, separated by a 14-day washout. Voriconazole pharmacokinetics were determined by noncompartmental analyses. A physiologically based pharmacokinetic model was developed in Simcyp (Simcyp Ltd., Sheffield, United Kingdom) to predict the magnitude of drug interaction should antifungal therapy be switched from fluconazole to voriconazole, following various simulated lag times for the switch. In CYP2C19 extensive metabolizers, fluconazole increased the maximum plasma concentration and the area under the plasma concentration-time curve (AUC) of voriconazole by 57% and 178%, respectively. In poor metabolizers, however, voriconazole pharmacokinetics were unaffected by fluconazole. The simulations based on pharmacokinetic modeling predicted that if voriconazole was started 6, 12, 24, or 36 h after the last dose of fluconazole, the voriconazole AUC ratios (sequential therapy versus voriconazole only) after the first dose would be 1.51, 1.41, 1.28, and 1.14, respectively. This suggests that the remaining systemic fluconazole would result in a marked drug interaction with voriconazole for \u226524 h. Although no safety issues were observed during coadministration, concomitant use of fluconazole and voriconazole is not recommended. Frequent monitoring for voriconazole-related adverse events is advisable if voriconazole is used sequentially after fluconazole.<\/jats:p>","DOI":"10.1128\/aac.00423-11","type":"journal-article","created":{"date-parts":[[2011,8,30]],"date-time":"2011-08-30T01:47:57Z","timestamp":1314668877000},"page":"5172-5177","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":54,"title":["Pharmacokinetics of Voriconazole Administered Concomitantly with Fluconazole and Population-Based Simulation for Sequential Use"],"prefix":"10.1128","volume":"55","author":[{"given":"Bharat","family":"Damle","sequence":"first","affiliation":[{"name":"Pfizer Inc., New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manthena V.","family":"Varma","sequence":"additional","affiliation":[{"name":"Pfizer Inc., Groton, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nolan","family":"Wood","sequence":"additional","affiliation":[{"name":"Pfizer Ltd., Sandwich, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2007.03084.x"},{"key":"e_1_3_2_3_2","unstructured":"European Medicines Agency. 2009. Vfend: EPAR\u2013product information (last updated January 2011). European Medicines Agency London United Kingdom. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000387\/human_med_001135.jsp&murl=menus\/medicines\/medicines.jsp&mid=WC0b01ac058001d125. Accessed 11 March 2011."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.31.5.540"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(97)90135-1"},{"key":"e_1_3_2_6_2","first-page":"739","article-title":"Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring","volume":"136","author":"Imhof A.","year":"2006","unstructured":"ImhofA. SchaerD. J. SchanzU. SchwarzU.. 2006. Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. Swiss Med. Wkly. 136:739\u2013742.","journal-title":"Swiss Med. Wkly."},{"key":"e_1_3_2_7_2","first-page":"853","article-title":"Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms","volume":"25","author":"Ko J.-W.","year":"1997","unstructured":"KoJ.-W. SukhovaN. ThackerD. ChenP. FlockhartD. A.. 1997. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab. Dispos. 25:853\u2013862.","journal-title":"Drug Metab. Dispos."},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1177\/00912700222011445"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.6.2.1371482"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2007.03.012"},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0022-3565(24)38103-0","article-title":"In vitro metabolism of quinidine: the (3S)-3-hydroxylation of quinidine is a specific marker reaction for cytochrome P-4503A4 activity in human liver microsomes","volume":"289","author":"Nielsen T. L.","year":"1999","unstructured":"NielsenT. L. RasmussenB. B. FlinoisJ. P. BeauneP. BrosenK.. 1999. In vitro metabolism of quinidine: the (3S)-3-hydroxylation of quinidine is a specific marker reaction for cytochrome P-4503A4 activity in human liver microsomes. J. Pharmacol. Exp. Ther. 289:31\u201337.","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.2165\/0003088-200847120-00003"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.28.1805"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1086\/524669"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.2147\/tcrm.2006.2.2.129"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.6.1723-1727.2002"},{"key":"e_1_3_2_17_2","unstructured":"Pfizer Inc. 2010. Diflucan\u2014U.S. prescribing information (revised January 2010). Pfizer Inc. New York NY."},{"key":"e_1_3_2_18_2","unstructured":"Pfizer Inc. 2010. Vfend\u2014U.S. prescribing information (revised June 2010). Pfizer Inc. New York NY."},{"key":"e_1_3_2_19_2","unstructured":"PrenticeA. G.. 2008. Guidelines on the management of invasive fungal infection during therapy for haematological malignancy. BCSH guidelines home page. Pfizer Inc. New York NY."},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.8.2546-2553.2002"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2003.01993.x"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.3.575"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2009.03534.x"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.5.5.883"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270005283837"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200645070-00002"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.2008.01725.x"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200038020-00002"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1086\/525258"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-008-0574-7"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270008327537"},{"key":"e_1_3_2_32_2","first-page":"610","article-title":"Formation of (R)-8-hydroxywarfarin in human liver microsomes. A new metabolic marker for the (S)-mephenytoin hydroxylase, P4502C19","volume":"24","author":"Wienkers L. C.","year":"1996","unstructured":"WienkersL. C.. 1996. Formation of (R)-8-hydroxywarfarin in human liver microsomes. A new metabolic marker for the (S)-mephenytoin hydroxylase, P4502C19. Drug Metab. Dispos. 24:610\u2013614.","journal-title":"Drug Metab. Dispos."},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2003.02000.x"},{"key":"e_1_3_2_34_2","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/S0022-3565(24)36606-6","article-title":"Differences in the incidence of the CYP2C19 polymorphism affecting the S-methenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele","volume":"281","author":"Xiao Z.-S.","year":"1997","unstructured":"XiaoZ.-S.. 1997. Differences in the incidence of the CYP2C19 polymorphism affecting the S-methenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. J. Pharmacol. Exp. Ther. 281:604\u2013609.","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2010.03656.x"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00423-11","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00423-11","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,9]],"date-time":"2025-03-09T11:39:20Z","timestamp":1741520360000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00423-11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":34,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["10.1128\/AAC.00423-11"],"URL":"https:\/\/doi.org\/10.1128\/aac.00423-11","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11]]},"assertion":[{"value":"2011-03-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-08-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-10-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}